Cytek Biosciences CEO advances flow cytometry for informed healthcare decision making

Cytek Biosciences CEO advances flow cytometry for informed healthcare decision making
Cytek Biosciences drives innovation

Cytek Biosciences CEO Dr. Wenbin Jiang outlines how flow cytometry is transforming strategic decision making across the healthcare sector.

In a Forbes Technology Council article, Dr. Jiang explains that advances in flow cytometry are enabling healthcare professionals to access more precise and actionable data, supporting faster and more informed choices at multiple levels of care. The technology, according to Dr. Jiang, is also driving broader innovation by empowering research and improving outcomes throughout the industry.

Cytek Biosciences recently announced a summer incentive program offering free gifts with reagent orders to boost customer purchases, according to a company statement. The firm is also backing research efforts that use spectral flow cytometry to evaluate vaccine effectiveness in older adults, as highlighted in its support for studies on vaccine responses in the elderly. These activities reflect Cytek's ongoing investment in both product offerings and scientific research.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.